Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8414774 | 0.97 | CYP2D6 (0.42) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL4597913 | 0.75 | IDO1 (0.38) | ALDH1A1LMNA | |
| SCHEMBL776297 | 0.74 | TSHR (0.38) | DPP4F2TSHRALDH1A1LMNA | |
| SCHEMBL193931 | 0.72 | CYP2D6 (0.48) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL548634 | 0.72 | CYP2D6 (0.48) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL4432460 | 0.72 | CYP2D6 (0.48) | CYP2D6SRCDPP4F2TSHR | |
| Hydrochloric Acid SCHEMBL11163950 | 0.72 | CYP2C19 (0.36) | DPP4F2TSHRALDH1A1LMNA | |
| Bicarbonate SCHEMBL8962406 | 0.72 | CYP2C19 (0.46) | CYP2D6SRCLMNAMAPK1CES2 | |
| SCHEMBL13184071 | 0.72 | CYP2D6 (0.43) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL4417704 | 0.70 | CYP2D6 (0.46) | CYP2D6SRCDPP4F2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683190-B1 | CONTACTING RACEMIC HYDANTOIN WITH ENANTIOMERIC SPLITTING AGENT; DECYCLIZATION | BAYER CROPSCIENCE S.A. (FR) | 2004-01-27 | — | — | US | claimed |
| EP-0551048-B1 | 2-imidazoline-5-one and 2-imidazoline-5-thiones derivatives as fungizides | AVENTIS CROPSCIENCE SA (FR) | 2002-08-07 | — | — | EP | claimed |
| EP-1076718-B1 | NOVEL METHOD FOR PREPARING SYNTHESIS INTERMEDIATES | AVENTIS CROPSCIENCE SA (FR) | 2002-05-02 | — | — | EP | claimed |
| WO-1995034541-A1 | FUNGICIDAL 5-IMINO-2-IMIDAZOLINE DERIVATIVES | RHONE POULENC AGROCHIMIE (FR) | 1995-12-21 | — | — | WO | claimed |
| EP-0648210-A1 | FUNGICIDAL 2-IMIDAZOLINE-5-ONE AND 2-IMIDAZOLINE-5-THIONE DERIVATIVES | RHONE-POULENC AGROCHIMIE (FR) | 1995-04-19 | — | — | EP | claimed |
| EP-0629616-A2 | Optically aktive 2-imidazolin-5-one and 2-imidazolin-5-thione derivatives as fungicides | RHONE-POULENC AGROCHIMIE (FR) | 1994-12-21 | — | — | EP | claimed |
| WO-1994001410-A1 | FUNGICIDAL 2-IMIDAZOLINE-5-ONE AND 2-IMIDAZOLINE-5-THIONE DERIVATIVES | RHONE POULENC AGROCHIMIE (FR) | 1994-01-20 | — | — | WO | claimed |
| EP-0551048-A1 | 2-imidazoline-5-one and 2-imidazoline-5-thiones derivatives as fungizides | RHONE-POULENC AGROCHIMIE (FR) | 1993-07-14 | — | — | EP | claimed |
| US-7833998-B2 | Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions | REVAAX PHARMACEUTICALS, LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080176825-A1 | Oral Neurotherapeutic Cefazolin Compositons | REVAAX PHARMACEUTICALS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-6759551-B1 | COMPOUND IS DISSOLVED, IN THE FREE AMINO ACID FORM OR IN THE SALIFIED FORM, IN A PH REGION OF LESS THAN APPROXIMATELY 4.5 OR GREATER THAN APPROXIMATELY 9, THEN PH IS GRADUALLY BROUGHT, BY ADDITION OF A BASE OR OF AN ACID RESPECTIVELY, TO NEUTRAL | BAYER CROPSCIENCE S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| US-6683190-B1 | CONTACTING RACEMIC HYDANTOIN WITH ENANTIOMERIC SPLITTING AGENT; DECYCLIZATION | BAYER CROPSCIENCE S.A. (FR) | 2004-01-27 | — | — | US | disclosed |
| EP-0551048-B1 | 2-imidazoline-5-one and 2-imidazoline-5-thiones derivatives as fungizides | AVENTIS CROPSCIENCE SA (FR) | 2002-08-07 | — | — | EP | disclosed |
| CN-1309659-A | Organic phosphorus compounds and their use | JOMAA HASSAN (DE) | 2001-08-22 | — | — | CN | disclosed |
| EP-0648210-A1 | FUNGICIDAL 2-IMIDAZOLINE-5-ONE AND 2-IMIDAZOLINE-5-THIONE DERIVATIVES | RHONE-POULENC AGROCHIMIE (FR) | 1995-04-19 | — | — | EP | disclosed |
| EP-0629616-A2 | Optically aktive 2-imidazolin-5-one and 2-imidazolin-5-thione derivatives as fungicides | RHONE-POULENC AGROCHIMIE (FR) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994001410-A1 | FUNGICIDAL 2-IMIDAZOLINE-5-ONE AND 2-IMIDAZOLINE-5-THIONE DERIVATIVES | RHONE POULENC AGROCHIMIE (FR) | 1994-01-20 | — | — | WO | disclosed |
| EP-0551048-A1 | 2-imidazoline-5-one and 2-imidazoline-5-thiones derivatives as fungizides | RHONE-POULENC AGROCHIMIE (FR) | 1993-07-14 | — | — | EP | disclosed |
| EP-0307476-A1 | BILIRUBIN ANTIGEN, MONOCLONAL ANTIBODY THEREFOR, PROCESS FOR THEIR PREPARATION, AND THEIR USE | KUKITA, Takeshi (JP) | 1989-03-22 | — | — | EP | disclosed |
| CN-1030074-A | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORP (US) | 1989-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176825-A1 | Oral Neurotherapeutic Cefazolin Compositons | BDNF, PRSS12, PYGB | CYP2D6 380/4885SRC 4565/4885DPP4 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.